

Helix BioMedix to Host Annual Meeting of Stockholders

Bothell, Washington—May 13, 2009 -- Helix BioMedix, Inc. (OTCBB: HXBM), a developer of bioactive peptides, today announced that its Annual Meeting of Stockholders will be held on Thursday, May 14, 2009, at 8:00 A.M. local time at the Country Inn & Suites, 19333 North Creek Parkway, Bothell, WA 98011. Proxy materials were mailed on or about April 10, 2009 to all stockholders of record as of March 19, 2009.

A live webcast of the meeting will be available on the company's website at: <http://www.helixbiomedix.com/proxyinformation>.

About Helix BioMedix, Inc.

Helix BioMedix, Inc. is a biopharmaceutical company with an extensive library of diverse bioactive peptides and patents covering six distinct classes and hundreds of thousands of peptide sequences. Our mission is to enrich clinical practice and the patient/consumer experience by developing topically-applied products which offer the health, beauty and safety benefits of our advanced bioactive small molecule technology. Our vision is to be recognized as the world leader in the identification, qualification and commercialization of natural and synthetic peptides.

Our core competencies include peptide design, synthesis and characterization together with assay development, screening, tissue culture and microbiology, leveraged through relationships with contract research organizations and peptide manufacturers. We have the capability to take our product development programs from theoretical concept to a validated and qualified skin care active ingredient fully validated as to efficacy and safety. Applications for Helix BioMedix peptides include anti-aging cosmeceutical skin care and acne treatment as well as other topical anti-infective pharmaceuticals and wound healing applications. In addition, we are developing finished, peptide-based products to market with our partners. Striking and SmartPeptide are trademarks of Helix BioMedix, Inc.

More information about the company and its proprietary peptides may be found on the company's website at www.helixbiomedix.com.

Investor Contact:

Ryan Bright
Shelton Group Investor Relations
(972) 239-5119 X 159
rbright@sheltongroup.com

Company Contact:

R. Stephen Beatty
President and CEO
(425) 402-8400
sbeatty@helixbiomedix.com